Savara (SVRA) Other Non-Current Assets (2010 - 2026)
Savara (SVRA) posted quarterly Other Non-Current Assets of $11.4 million for Q1 2026, up 5.88% year-over-year from $10.7 million in Q1 2025, and down 2.34% quarter-over-quarter from $11.6 million in Q4 2025.
Savara (SVRA) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Other Non-Current Assets for 17 consecutive years, with $11.4 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Assets rose 5.88% year-over-year to $11.4 million; the TTM figure through Mar 2026 stood at $11.4 million (up 5.88% YoY), while the FY2025 annual figure was $11.6 million, up 12.97% from the prior year.
- Other Non-Current Assets eased to $11.4 million in Q1 2026 per SVRA's latest filing, from $11.6 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $11.6 million in Q4 2025 and bottomed at $116000.0 in Q4 2022.
- Historically, Other Non-Current Assets has averaged $8.4 million across 5 years, with a median of $10.7 million in 2024.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets slumped 98.97% — and 2024, when it surged 2561.5%.
- Savara's Other Non-Current Assets stood at $116000.0 in 2022, then jumped by 233.62% to $387000.0 in 2023, then soared by 2561.5% to $10.3 million in 2024, then increased by 12.97% to $11.6 million in 2025, then declined by 2.34% to $11.4 million in 2026.
- Business Quant data shows SVRA's Other Non-Current Assets at $11.4 million in Q1 2026, $11.6 million in Q4 2025, and $990000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 11.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.29 Mn |
| Mar 31, 2026 | 11.36 Mn |
| Dec 31, 2025 | 11.64 Mn |
| Sep 30, 2025 | 990,000.00 |
| Jun 30, 2025 | 11.63 Mn |
| Mar 31, 2025 | 10.73 Mn |
| Dec 31, 2024 | 10.30 Mn |
| Sep 30, 2024 | 11.11 Mn |
| Jun 30, 2024 | 10.63 Mn |
| Mar 31, 2024 | 10.71 Mn |
| Dec 31, 2023 | 387,000.00 |
| Sep 30, 2023 | 10.50 Mn |
| Jun 30, 2023 | 10.78 Mn |
| Mar 31, 2023 | 10.82 Mn |
| Dec 31, 2022 | 116,000.00 |
| Sep 30, 2022 | 9.75 Mn |
| Jun 30, 2022 | 952,000.00 |
| Mar 31, 2022 | 11.06 Mn |
| Dec 31, 2021 | 11.27 Mn |
| Sep 30, 2021 | 1.05 Mn |